New facility in Texas will have capabilities for process and analytical development and manufacturing services for CAR-T, IPSC, MSC and cell therapies.
Projects include upgrades to existing analytical services, the installation of new equipment, including reactors, filter dryers, and distillation units.
Partnership network combines the power of automated CRISPR cell line engineering with phenotypic, functional and multi-omic assays to optimize research work.
Offers analytical method validation and analytical services to support batch release, in additional to stability studies to enable rapid regulatory filing.